This is an interesting perspective on the TIGIT landscape. I'm curious to learn more about this recent news and how it will impact the future of this class of drugs.
Sally (Karim) Bartlett’s Post
More Relevant Posts
-
How has Propanc Biopharma optimized the formulation of their lead asset? We invite you to listen as Dr. Ralf Brandt, Propanc’s Scientific Advisory Board Member & Co-Inventor describes the process for taking the formulation from that compassionate use study that observed such positive results, and how the team further improved that same formulation with the goal of seeing even more efficacious results! #propanc #ppcb #biopharma #cancer #oncology
-
Login to RxTROSPECT and use analytics to help navigate an optimal approval pathway for your NDA/BLA. Contact us today for trial access and a demo #oncology #biotech #biotechnology #regulatoryaffairs #pharma #drugdevelopment #oncologytrials #oncologyresearch #cancer #oncology #regulatoryintelligence #regulatoryprecedent
-
🎙️ Bulls ‘n Bears #Amplia CEO and MD Chris Burns spoke with Bulls ‘n Bears host, Matt Birney, this week to discuss the Company’s progress on ACCENT trial investigating FAK-inhibitor narmafotinib (AMP945) in pancreatic cancer. Dr. Burns shared positive early results from the Phase 2a trial, which initially enrolled 26 patients: “𝘐𝘵’𝘴 𝘦𝘢𝘳𝘭𝘺 𝘥𝘢𝘺𝘴, 𝘣𝘶𝘵 𝘸𝘦’𝘷𝘦 𝘢𝘭𝘳𝘦𝘢𝘥𝘺 𝘴𝘦𝘦𝘯 𝘴𝘪𝘹 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘴𝘩𝘰𝘸 𝘢 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵 𝘳𝘦𝘥𝘶𝘤𝘵𝘪𝘰𝘯 𝘪𝘯 𝘵𝘩𝘦𝘪𝘳 𝘵𝘶𝘮𝘰𝘶𝘳 𝘴𝘪𝘻𝘦, 𝘢𝘯𝘥 𝘸𝘦’𝘷𝘦 𝘩𝘢𝘥 𝘢𝘯𝘰𝘵𝘩𝘦𝘳 𝘴𝘪𝘹 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘴𝘩𝘰𝘸 𝘴𝘵𝘢𝘣𝘭𝘦 𝘥𝘪𝘴𝘦𝘢𝘴𝘦 𝘰𝘷𝘦𝘳 𝘵𝘪𝘮𝘦. 𝘐𝘵’𝘴 𝘢 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘪𝘯𝘨 𝘥𝘢𝘵𝘢 𝘴𝘦𝘵, 𝘣𝘶𝘵 𝘸𝘦’𝘳𝘦 𝘢𝘭𝘳𝘦𝘢𝘥𝘺 𝘱𝘳𝘦𝘵𝘵𝘺 𝘦𝘹𝘤𝘪𝘵𝘦𝘥 𝘢𝘣𝘰𝘶𝘵 𝘵𝘩𝘢𝘵 𝘥𝘢𝘵𝘢, 𝘢𝘯𝘥 𝘸𝘦 𝘤𝘢𝘯 𝘯𝘰𝘸 𝘳𝘦𝘤𝘳𝘶𝘪𝘵 𝘢 𝘧𝘶𝘳𝘵𝘩𝘦𝘳 24 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘵𝘳𝘪𝘢𝘭.” Have a listen 👉 https://bit.ly/ATX-3AW $ATX #Amplia #pancreaticcancer #clinicaltrial #cancertherapeutics #invest #innovation #pharma
-
#AACR24, here we come! We can’t wait to share with you the latest from our #DrugDiscovery labs next Monday. Here’s a preview 👇 💡 Abstract 2945 / 20: Find out how our #FunctionalGenomicsCentre’s teams are reducing the experimental scale of #CRISPR screens by 50%. 💡 Abstract 3333 / 21: Learn about ASTX295, a potent inhibitor of the MDM2-p53 interaction currently under clinical investigation. Are you presenting at #AACR24? Let us know where and when in the comments. #OnMyHorizon #Oncology Steve Wedge, David Walter, Astex Pharmaceuticals and American Association for Cancer Research
-
As #oncology continues to drive growth in the global pharma market, there is increasing interest in new combinations and drug modalities. Explore the trends and innovation shaping the future of #cancer care in this new blog. https://bit.ly/3UQngTJ #IQVIAMIDAS #AnalyticsLink
-
Katrina Pedersen, MD, shared her excitement about cancer clinical trials in myTRIAList's AZUR-1 study overview video. To keep up to date on the latest trial-overview videos in CancerCare's myTRIAList Trial Finder, subscribe to our YouTube channel here: https://buff.ly/4bDeAWs #oncology #clinicaltrials #pharma #md #biotech #cancerresearch
AZUR-1 Investigator Teaser
-
Dr. William V. Williams, BriaCell’s President & CEO, shares insight on the Company's positive feedback received from its Pre-IND meeting with the FDA for Bria-PROS+™ in #prostatecancer. Learn more: https://bit.ly/3TmeEDc #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #personalizedcancerimmunotherapies #personalizedcancerdrugs #breastcancer #lungcancer #melanoma #noveldrugs #MBC
-
➡ Our colleagues, Oscar Salamanca, CEO, and Ana Moreno, Director Global Clinical Operations (APICES CRO), are sharing the latest advances in clinical #cancer research at #ASCO24, the largest #oncology event in the world. #clinicalresearch #clinicaltrials #Healthcare #Pharma #Biotech #HealthcareInnovation #CRO --- Nuestros compañeros, Oscar Salamanca (CEO) y Ana Moreno, Director Global Clinical Operations (APICES CRO), están compartiendo los últimos avances en #investigacionclinica en #cancer, en #ASCO24, el mayor evento mundial de #oncologia. #ensayosclinicos
-
-
Together with our partner Jazz Pharmaceuticals, we look forward to presenting at #ESMO24 and providing updated results for the treatment of HER2-positive metastatic gastroesophageal adenocarcinoma and other HER2-positive cancers. #breastcancer #colorectalcancer
We will be presenting five #oncology abstracts at #ESMO24 alongside our partners, including updated data showcasing the potential of an investigational dual HER2-targeted bispecific antibody in treating HER2-positive metastatic gastroesophageal adenocarcinoma. Learn more here: https://lnkd.in/eBFP_R6q
-